Tumor lysis syndrome


Authors: A. Kafková ;  E. Tóthová
Authors‘ workplace: Klinika hematológie a onkohematológie Lekárskej fakulty UPJŠ a FNsP Košice, Slovenská republika, prednosta prof. MUDr. E. Tóthová, CSc.
Published in: Vnitř Lék 2005; 51(2): 216-220
Category: Reviews

Overview

Tumor lysis syndrome with hypeuricemia, also known as TLS, is a potentially serious complication of cancer chemotherapy and it can result in life–threatening complications such as renal failure and cardiac arrhythmias. The aim of this paper is to provide a general overview of the pathophysiology and corresponding signs and symptoms of TLS and review clinical and laboratory monitoring parameters. An understanding of the pathophysiology of TLS and meticulous assessment of signs and symptoms and monitoring of the laboratory data, as well as early recognition of problems are essential for optimal patient outcomes. Both allopurinol and rasburicase offer flexibility in the management of TLS and may allow for further avoidance of the consequences of inadequate management of this syndrome.

Key words:
tumor lysis syndrome – chemotherapy – pathophysiology – treatment – prevention


Sources

1. Abou Mourad Y, Taher A, Shamseddine A. Acute tumor lysis syndrome in large B-cell non-Hodgkin’s lymphoma induced by steroids and anti-CD20. Hematol J 2003; 4(3): 222–224.

2. Alkhuja S, Ulrich H. Acute renal failure from spontaneous acute tumor lysis syndrome: A case report and review. Ren Fail 2002; 24(2): 227–232.

3. Altman A. Acute tumor lysis syndrome. Semin Oncol 2001; 28(Suppl 5): 3–8.

4. Annemans L, Moeremans K, Lamotte M et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumor lysis syndrome in haematological cancer patients. Support Care Cancer 2003; 1154: 249–257.

5. Basile C, Montranaro A. An exceptionally severe hyperuricemia in acute renal failure from spontaneos tumor lysis syndrome (TLS). G Ital Nefrol 2003; 20(5): 525–528.

6. Barry BD, Kell MR, Redmond HP. Tumor lysis syndrome following endoscopic radiofrequency intestinal thermal ablation of colorectal liver metastases. Surg Endosc 2002; 16(7): 1109.

7. Bishop MR, Coccia PF. Tumor lysis syndrome. In: Abeloff MD et al. Clinical Oncology. 2nd ed. New York: Churchill Livingstone 2000: 750–753.

8. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer. Part II. Am J Health Syst Pharm 2003; 60(16): 1631–1641.

9. Cersosimo RJ. Monoclonal antibodies in the treatment of Cancer Part I. Am J Health Syst Pharm 2003; 60(15): 1531–1548.

10. Coiffier B, Mounier N, Bologna S et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: Results of the GRAAL 1 (Groupe d’Etude des lymphomes de l’adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol 2003; 21(23): 4402–4406.

11. Doane L. Overview of tumor lysis syndrome. Semin Oncol Nurs 2002; 18 (Suppl 3): 2–5.

12. Flombaum CD. Metabolic emergencies in the cancer patients. Semin Oncol 2000; 27: 322–334.

13. Goldman SC. Rasburicase: Potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003; 3(4): 429–433.

14. Greenwood MJ, Dodds AJ, Garricik R et al. Posterior leukoencephalopathy in association with the tumor lysis syndrome in acute lymphoblastic leukaemia: A case with clinicopathological correlation: Leuk Lymphoma 2003; 44(4). 719–721.

15. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med 1993; 94. 133–139.

16. Holdsworth MT, Nguyen P. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm 2003; 60(21): 2213–2222.

17. Hussain K, Mazza JJ, Clouse LH. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol 2003; 72(3): 212–215.

18. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: Pathogenesis and management. Pediatr Nephrol 1995; 9(9): 206–212.

19. Kaplow R. Pathofysiology, sign, and symptoms of acute tumor lysis syndrome. Semin Oncol Nurs 2002; 18(Suppl 3): 6–11.

20. Kopečná L, Doležel Z, Osvaldová Z et al. The analysis of the risks for the development of tumor lysis syndrome in children. Bratisl Lek Listy 2002; 103(6): 206–209.

21. Lerza R, Botta M, Barsotti B et al. Dexamethazone-induced acute tumor lysis syndrome in T-cell malignant lymphoma. Semin Oncology 2002; 18(3): 6–9.

22. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003; 30(4): 483–492.

23. Linck D, Basara N, Tran V et al. Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduction intensity preparative regimen in patients with T-ALL with high tumor burden. Bone Marrow Transplant 2003; 31(10): 935–937.

24. Milano GM, deSio L, Cozza R et al. Tumor lysis syndrome and neuroblastoma. Med Pediatr Oncol 2003; 41(6): 542.

25. Mayer J, Starý J et al. Leukémie. Praha: Grada 2002: 164–167.

26. Patte C, Sakiroglu C, Ansoborlo S et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe francaise d’Oncologie pediatrique LMB 89 protocol. Ann Oncol 2002; 13(5): 789–795.

27. Pui CH, Jeha S, Irwin D et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy–associated hyperuricaemia in pediatric and adult patients: Results/of a compassionate-use trial. Leukemia 2002; 15: 1505–1509.

28. Pui CH, Mahmoud HH, Wiley JM. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697–704.

29. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malognancies. Clin Lymphoma 2003; 3(4): 225–232.

30. Stapleton FB, Strother DR, Roy S et al. Acute renal failure at oncet of therapy for aduanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 1988; 82: 863–869.

31. Seftel MD, Bruyere H, Copland M et al. Fulminant tumor lysis syndrome in acute myelogenous leukaemia with inv (16) (p13;q22). Eur J Haematol 2002; 69(4): 193–199.

32. Seidemann K, Meyer U, Jansen P et al. For the BFM-Study Group: Impaired renal function and tumor lysis syndrome in pediatrics patients with non-Hodgkin’s lymphoma and B-ALL. Klin Pädiatr 1998; 210: 279–284.

33. Seki JT, Al–Omar HM, Amato D et al. Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. Ann Pharmacother 2003; 37(5): 675–678.

34. Stucky LA. Acute tumor lysis syndrome: Assessment and nursing implications. Oncol Nurs Forum 1993; 20: 49–59.

35. Tomera JF. Acute tumor lysis syndrome: Considerations of cause and prevention. Drugs Today (Barc) 1999; 35(2); 79–87.

36. Vaisban E, Braester A, Mosenzon O et al. Spontaneous tumor lysis syndrome in solid tumors: Really a rare condition? Am J Med Sci 325(1), 38–40.

37. Yang SS, Chau T, Dai MS et al. Stereoid-induced tumor lysis syndrome in a patient with preleukemia. Clin Nephrol 2003; 59(3); 201–205.

38. Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta 2003; 333(1): 13–18.

39. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003; 37(7–8): 1047–1054.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 2

2005 Issue 2

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account